Study guide

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers

Key Takeaways Explain This Topic AI

Class of Case [610] classifies the facility's role: analytic cases (00–22) were diagnosed and/or received first-course treatment at the facility; nonanalytic cases (30–99) were not, or were diagnosed before the reference date.

Date of First Contact [580] is the date the patient first became analytic at the facility (or, for nonanalytic cases, the date the nonanalytic status began); it is updated if a nonanalytic case later becomes analytic.

Date of Initial Diagnosis [390] is the first date of a clinical or histologic diagnosis by a physician, anywhere; when a positive pathology report is the only information, it is the date of the procedure, not the date the report was read.

Accession Number [550] is nine digits (first-contact year plus a five-digit sequence), identifies the patient permanently, and is never reassigned or changed once submitted.

Sequence Number [560] is 00 for the only malignant or in situ primary and changes to 01 when a second primary is diagnosed; non-malignant primaries use a separate 60–88 series.

Last updated: September 2026

Why these items belong together

Class of Case, the dates and the identifiers decide whether a case is analytic (and therefore submitted to the NCDB, followed, and counted in quality measures), when the clock starts for timeliness, staging and treatment, and how the patient and each tumor are identified permanently. Many exam questions combine them: "Which Class of Case, and what Date of First Contact?"

Class of Case [610]: the big picture

Group Codes Meaning CoC requirement

Analytic 00, 10–14, 20–22 Diagnosed and/or administered any first-course treatment at the facility, diagnosed on or after the reference date, and a type of tumor CoC requires Accession, abstract, submit to NCDB. Stage and follow classes 10–22; class 00 need not be staged or followed.

Nonanalytic 30–38, 40–43, 49, 99 Everything else, including consult-only, in-transit care, recurrence after care elsewhere, history only, tumor types CoC does not require, cases diagnosed before the reference date, autopsy discoveries, physician-office-only, pathology-only and death certificate only Not required by CoC; may be required by the cancer committee or the state

STORE ties facility boundaries to the hospital's Federal Employer Identification Number (FEIN) . Services covered by the facility's FEIN generally count as "the facility" for analytic status. Care given in a staff physician's own office is coded as given "elsewhere," because the hospital is not responsible for it.

Sections 11.2 and 11.3 define each code.

Date of First Contact [580]

Definition: the date of the facility's first inpatient or outpatient contact with the patient for diagnosis or treatment of this cancer . For analytic cases, it is the date the patient qualified as analytic .

Usually it is the date of admission or the outpatient visit for diagnosis or treatment, including a visit for a biopsy, x-ray or laboratory test.

If the patient was admitted for something else, it is the date cancer was first suspected during that stay.

If a nonanalytic case becomes analytic (for example, from Class of Case 30 consult-only to Class of Case 21 when the patient returns for treatment), update Date of First Contact to the date the case became analytic.

Class 00 changes to 13 or 14 when a patient diagnosed at the facility, who went elsewhere for treatment, returns for treatment that was expected elsewhere. The Date of First Contact does not change, because it still marks when the patient became analytic.

For a Class 40 case (diagnosed and treated entirely in a staff physician's office), it is the date the physician first diagnosed the cancer. For autopsy-only cases, it is the date of death. For Class 43 (pathology only), it is the date the specimen was collected.

Date of Initial Diagnosis [390]

Use the first date of diagnosis, whether clinical or histologic , made by a physician at any facility.

If the physician later says the patient in retrospect had cancer at an earlier date, use the earlier date.

Ambiguous terms from the reportable list establish a diagnosis date when they are later confirmed. STORE example: pathology "suspicious for cancer" on May 17, confirmed positive May 22, so the date of diagnosis is May 17 .

Suspicious cytology later proven by biopsy: use the cytology date. STORE example: cytology suspicious June 12, pathology positive July 2, so the date of diagnosis is June 12 .

If treatment starts before a diagnosis is documented, use the date treatment started.

For autopsy-only (Class 38) and death-certificate-only (Class 49) cases, the date of diagnosis is the date of death .

If only the year is known, record the year and leave the month and day unknown. If only a season is documented, STORE approximates: spring = April, summer or mid-year = July, fall = October.

Procedure date, not report date: the SEER manual states that when a positive pathology or cytology report is the only information, the date of diagnosis is the date the procedure was done , not the date the specimen was received, read or signed out.

Accession Number [550]

Nine digits: the first four are the year of first contact for a reportable tumor, and the last five are the order of accession within that year (for example, 202600215).

One accession number per patient, for life . All of the patient's primaries share it.

Accession numbers are never reassigned , even if a patient is removed from the registry. Once submitted to RCRS or the NCDB they are never changed , even for a clerical error or when an older case is found out of order.

Sequence Number [560] (Hospital)

Series Codes Rule

Malignant or in situ (behavior 2 or 3) 00 = only one in the lifetime; 01, 02, … 59 = order among two or more; 99 = unknown number Change 00 to 01 when a later malignant or in situ primary occurs, then number the rest in order

Non-malignant (behavior 0 or 1) 60 = only one; 61, 62, … 87 = order among two or more; 88 = unspecified number Change 60 to 61 when a later non-malignant primary occurs

More STORE rules:

Count every reportable tumor in the patient's history , including those diagnosed or treated elsewhere and never accessioned by you. STORE example: a patient with three prior malignancies elsewhere, admitted for colon surgery, gets sequence 04 for the colon cancer.

Simultaneous primaries: give the lower sequence number to the one with the worse prognosis . If prognosis is the same, the choice is arbitrary.

Update sequence numbers if you later learn of an earlier, unaccessioned reportable tumor. Do not renumber if a previously reportable tumor later becomes non-reportable under a rule change.

Central registries record their own Sequence Number–Central [380] , which follows the same concept and may include tumors your hospital never saw.

Worked timeline

March 4: colonoscopy at the hospital shows a mass, and a biopsy is taken.

March 8: the pathology report is signed out (adenocarcinoma).

March 25: colectomy at the same hospital.

Result: Date of First Contact = March 4 . Date of Initial Diagnosis = March 4 (the date the biopsy was taken; the physician's endoscopic impression that day may also support it). Class of Case = 14 (diagnosed at the facility and all first-course treatment at the facility).

Loading diagram... Key case-identification items